Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Targets of BTK and IRAK4 pathways in cns lymphoma: Identification of CXCL10 as a prognostic biomarker in CSF and its receptor, CXCR3, as a mediator of pro-survival signaling

Ming Lu, Huimin Geng, Lingjing Chen, Lisa Drew, Andrew Bloecher, Courtney Andersen, Aylin Saleh, Pasha Fooman, Clifford Lowell, James Rubenstein

Blood (2025) 146 (Supplement 1): 5321.

https://doi.org/10.1182/blood-2025-5321

Published: 2025

Journal Articles

The effects of bruton tyrosine kinase inhibitors on the waldenstrom macroglobulinemia microenvironment

Stephen Blackmore, Rachel Zawacki, Collin Tokheim, Lisa Drew, Omid Tavana, Sherine Elsawa

Blood (2025) 146 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2025-1786

Published: 2025

Journal Articles

Identification of novel, potent, and selective JAK2V617F inhibitors

Blood (2025) 146 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2025-4326

Published: 2025

Journal Articles

Development and characterization of a potent and selective BLIMP1 protac as a novel, first-in-class therapy for multiple myeloma

Blood (2025) 146 (Supplement 1): 2554.

https://doi.org/10.1182/blood-2025-2554

Published: 2025

Journal Articles

Discovery of UBE2B and RNF144b As Potential Candidates for Selective Degradation of NPM1c in AML

Neeraj K Aryal, Thomas Frost, Yuhan Huang, Bo Kyung Alex Seong, Lisa Drew, Omid Tavana

Blood (2024) 144 (Supplement 1): 4969.

https://doi.org/10.1182/blood-2024-208385

Published: 2024

Journal Articles

A Multi-Modal Analysis of Acquired Resistance to Acalabrutinib and Pirtobrutinib Provides Potential Strategies to Augment Treatment Outcome with BTKi Drugs

Xiaoyun Wu, Shariful Islam, Derek B Oien, Collin Tokheim, Alex Beacom, Neeraj Aryal, Michelle Hsueh, Muskan Floren, Douglas Ross-Thriepland, Daniel Barrell, Ultan McDermott, Veerendra Munugalavadla, Daniel Auclair, Simon Rule, Arthur Shaffer, Jude Fitzgibbon, Lisa Drew

Blood (2023) 142 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2023-189924

Published: 2023

Journal Articles

Transient CDK9 Inhibition with AZD4573 Effectively Induces Apoptosis in Burkitt Lymphoma As a Monotherapy in Pre-Clinical Models

Danielle S Potter, India Ott, Jamal Saeh, Stephen Fawell, Lisa Drew, Justine Roderick-Richardson

Blood (2023) 142 (Supplement 1): 5013.

https://doi.org/10.1182/blood-2023-189128

Published: 2023

Journal Articles

AZD4573 in Combination with CHOP Increases Combination Benefit in Preclinical Peripheral T-Cell Lymphomas Models

Danielle S Potter, India Ott, Jamal Saeh, Richard Olsson, Stephen Fawell, Lisa Drew, Justine Roderick-Richardson

Blood (2023) 142 (Supplement 1): 7133.

https://doi.org/10.1182/blood-2023-179419

Published: 2023

Journal Articles

Establishing an AML Ex Vivo Platform to Generate Physiologically Relevant Models

Omid Tavana, Brandon Willis, Siyu Liu, Amanda Christie, Courtney L Andersen, Justine Roderick-Richardson, Amanda Robichaud, Laura Prickett, Corinne Reimer, Lisa Drew

Blood (2023) 142 (Supplement 1): 7136.

https://doi.org/10.1182/blood-2023-177856

Published: 2023

Journal Articles

Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma

Neeraj K Aryal, Anjana Sundarrajan, Scott Boiko, David Jenkins, Huayang Liu, Miika Ahdesmaki, Aurelie Bornot, Andrew Jarnuczak, Eric Miele, Ultan McDermott, Stephen Fawell, Lisa Drew, Larry H. Boise, Justin Cidado

Blood (2021) 138 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2021-151194

Published: 2021

Journal Articles

AZD4573 Effectively Induces Apoptosis in r/r MCL As a Monotherapy or in Combination with Acalabrutinib

Justine Roderick, Scott Boiko, Courtney L Andersen, Huiling Liang, Gregory Dowdell, Corinne Reimer, Lisa Drew, Danielle M Townsley, Justin Cidado

Blood (2021) 138 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2021-151725

Published: 2021

Journal Articles

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P. Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C. Saeh, Stephen E. Fawell, Ricky W. Johnstone, Lisa Drew, Justin Cidado

Blood (2021) 137 (21): 2947–2957.

https://doi.org/10.1182/blood.2020008528

Published: 2021

Includes: Supplemental data

Journal Articles

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Bing Z Carter, PhD, Po Yee Mak, Steven M. Kornblau, MD, Wenjing Tao, Yuki Nishida, MD PhD, Vivian Ruvolo, MS, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1271.

https://doi.org/10.1182/blood-2019-124826

Published: 2019

Journal Articles

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Bing Z Carter, PhD, Po Yee Mak, Marc Warmoes, Wenjing Tao, Philip Lorenzi, Vivian Ruvolo, MS, Lin Tan, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3727.

https://doi.org/10.1182/blood-2019-124453

Published: 2019

Journal Articles

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, Kay Shigemori, Sara N. Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A. Brem, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai, David M. Weinstock

Blood (2019) 133 (6): 566–575.

https://doi.org/10.1182/blood-2018-07-865527

Published: 2019

Includes: Supplemental data

Journal Articles

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Mark Warmoes, Philip L Lorenzi, PhD, Duncan Mak, BSc, MPhil, Vivian Ruvolo, MS, Xiangmeng Wang, Huaxian Ma, MS, Hong Mu, MD PhD, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 768.

https://doi.org/10.1182/blood-2018-99-113491

Published: 2018

Journal Articles

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Justin Cidado, PhD, Scott Boiko, MS, Theresa Proia, PhD, Haley Woods, MS, Omid Tavana, PhD, Maryann San Martin, MS, Adriana E. Tron, PhD, Wenlin Shao, PhD, Lisa Drew, PhD

Blood (2018) 132 (Supplement 1): 3946.

https://doi.org/10.1182/blood-2018-99-113423

Published: 2018

Journal Articles

Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma

Huimin Geng, PhD, Brice Tiret, PhD, Hua-Xin Gao, PhD, Cigall Kadoch, PhD, Ming Lu, PhD, Lingjing Chen, PhD, Ilwoo Park, PhD, Gerd Melkus, PhD, Adam Elkhaled, PhD, John Kurhanewicz, PhD, Lisa Drew, PhD, Sebastien Degorce, PhD, Michele Mayo, PhD, Keith Dillman, PhD, Rana Anjum, PhD, Andrew Bloecher, PhD, Myriam Chaumeil, PhD, James Rubenstein, MD, PhD

Blood (2018) 132 (Supplement 1): 2840.

https://doi.org/10.1182/blood-2018-99-117625

Published: 2018

Journal Articles

Overcoming MCL1 Resistance in Multiple Myeloma

Ka Tat Siu, PhD, Cherrie Huang, Cristina Panaroni, PhD, Kenta Mukaihara, MD PhD, Keertik Fulzele, PhD, Rosemary Soucy, Justin Cidado, PhD, Lisa Drew, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 472.

https://doi.org/10.1182/blood-2018-99-116377

Published: 2018

Journal Articles

Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Taylor Rowland, Cody Paiva, BS, Joelle Rowley, Andy Chen, MD PhD, Lisa Drew, PhD, Peter Hurlin, Bill H. Chang, MD PhD, Alexey V Danilov, MD PhD

Blood (2016) 128 (22): 289.

https://doi.org/10.1182/blood.V128.22.289.289

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targets of BTK and IRAK4 pathways in cns lymphoma: Identification of CXCL10 as a prognostic biomarker in CSF and its receptor, CXCR3, as a mediator of pro-survival signaling

The effects of bruton tyrosine kinase inhibitors on the waldenstrom macroglobulinemia microenvironment

Identification of novel, potent, and selective JAK2V617F inhibitors

Development and characterization of a potent and selective BLIMP1 protac as a novel, first-in-class therapy for multiple myeloma

Discovery of UBE2B and RNF144b As Potential Candidates for Selective Degradation of NPM1c in AML

A Multi-Modal Analysis of Acquired Resistance to Acalabrutinib and Pirtobrutinib Provides Potential Strategies to Augment Treatment Outcome with BTKi Drugs

Transient CDK9 Inhibition with AZD4573 Effectively Induces Apoptosis in Burkitt Lymphoma As a Monotherapy in Pre-Clinical Models

AZD4573 in Combination with CHOP Increases Combination Benefit in Preclinical Peripheral T-Cell Lymphomas Models

Establishing an AML Ex Vivo Platform to Generate Physiologically Relevant Models

Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma

AZD4573 Effectively Induces Apoptosis in r/r MCL As a Monotherapy or in Combination with Acalabrutinib

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma

Overcoming MCL1 Resistance in Multiple Myeloma

Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only